Showing results (11-20 of 30) with videos related to
Sort By:
Pageof 3
American Journal of Therapeutics|May 17, 2014
Effects of Extended-Release Niacin and Extended-Release Niacin/Laropiprant on the Pharmacokinetics of Simvastatin in Healthy SubjectsBrett Lauring, Victor Dishy, Pieter-Jan De Kam, et al.Diabetes, Obesity & Metabolism|September 1, 2017
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)Julio Rosenstock, Juan Frias, Dénes Páll, et al.Journal of Clinical Pharmacology|March 12, 2014
Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteersBrett Lauring, Yang Liu, Xiujiang Susie Li, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 22, 2017
Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized StudyGeorge Grunberger, Sarah Camp, Jeremy Johnson, et al.Journal of Clinical Pharmacology|October 17, 2009
Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjectsBrett Lauring, Victor Dishy, Wen-Lin Luo, et al.Diabetes, Obesity & Metabolism|January 25, 2017
Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise aloneSteven G Terra, Kristen Focht, Melanie Davies, et al.Current Medical Research and Opinion|May 27, 2017
A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapyYehuda Handelsman, Brett Lauring, Ira Gantz, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 10, 2018
Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized StudySam Miller, Tania Krumins, Haojin Zhou, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|December 29, 2017
Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized StudyPriscilla Hollander, Jie Liu, Julie Hill, et al.Current Medical Research and Opinion|February 15, 2019
Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metforminPriscilla Hollander, Julie Hill, Jeremy Johnson, et al.Pageof 3